Anne Schaefer (scientist)

Last updated
Anne Schaefer
NationalityGerman
Alma materM.D. Johannes Gutenberg University Mainz in Germany, M.D. Charite University Berlin, in Germany, Postdoctoral Work The Rockefeller University
Known forDeveloping the TRAP technique to reveal transcriptional profiles by isolating ribosome associated mRNA
AwardsInventor of the Year 2018 Award, Inaugural NINDS Landis Award for Outstanding Mentorship, Harold and Golden Lamport Research Award, Kavli Frontiers in Science Fellow, Cure Challenge Award, Technology Development Fund Award, NIH Director’s New Innovator Award, Seaver Autism Center Research Award, 2010 NARSAD Young Investigator Award, German Research Foundation DFG Research Fellowship, Hans-Hench Award 2005 German Society for Immunology, USA-Scholarship of the German National Merit Foundation
Scientific career
FieldsNeuroscience, genetics, immunology
InstitutionsIcahn School of Medicine at Mount Sinai, The Rockefeller University

Anne Schaefer is a neuroscientist, professor of Neuroscience, vice-chair of Neuroscience, and director of the Center for Glial Biology at the Icahn School of Medicine at Mount Sinai in New York City. Schaefer investigates the epigenetic mechanisms of cellular plasticity and their role in the regulation of microglia-neuron interactions. Her research is aimed at understanding the mechanisms underlying various neuropsychiatric disorders and finding novel ways to target the epigenome therapeutically.

Contents

Early life and education

Schaefer started her medical training at Johannes Gutenberg University Mainz in Germany from 1996 until 1999. [1] Schaefer continued her education by pursuing her MD at the Charite University Berlin, in Germany. [2] She worked under the mentorship of Dr. Ralf Ignatius and then in 2001, Schaefer won the USA-Scholarship of the German National Merit Foundation and to pursue a research internship at The Rockefeller University. [1] As a Visiting Student, Schaefer worked under the mentorship of Dr. Michel Nussenzweig at Rockefeller studying immunology, specifically the adaptive immune lymphocytes called B cells. [3] In her research, she helped discover that 55-75% of the antibodies produced by immature B cells are actually auto-reactive and these B cells are removed from the population during two discrete check points in B cells development. [4]

After her research internship, Schaefer stayed in New York City to complete a Medical Internship at Weill Cornell Medical College within the Sloan Kettering Cancer Center in 2003. [2] Schaefer graduated from Charite University in 2004. [2]

Schaefer came back to Rockefeller in 2004 to pursue postdoctoral training under the mentorship of Dr. Paul Greengard. [1] In the Greengard Lab, Schaefer switched her research focus in the direction of neuroscience and explored epigenetic regulation of neural physiology. [3]

Career and research

Schaefer remained in Greengard’s lab as a research associate from 2007 to 2009 and was promoted to Senior Research Associate in 2009. [2] She held this title until she started her own lab at Mount Sinai School of Medicine in 2011. [5] Schaefer is currently a tenured professor in the Department of Neuroscience and Psychiatry at the Friedman Brain Institute at Mount Sinai School and remains an adjunct faculty member at Rockefeller University. [1] In 2012 named the Chrissy Rossi Investigator at Mount Sinai. [6] In 2017, Schaefer co-founded the Center for Glial Biology at Mount Sinai and is now the co-director of the center alongside Dr. Patrizia Casaccia. [6] As of 2018, Schaefer was promoted to vice-chair of Neuroscience at Sinai. [1] The Schaefer Lab studies the epigenetic mechanisms of cellular plasticity, maintenance of neuronal identity, as well as the role of epigenetics in regulating neuron-microglia interactions. [6] One of the goals of her lab is to develop tools and therapies with which to target the epigenome to treat neurological disorders. [6]

The neuronal epigenome

In 2007, Schaefer published a first author paper discussing the importance of microRNAs (miRNAs) in the regulation of neuronal gene expression. [7] She showed that a conditional knockout of the miRNA generating enzyme, Dicer, lead to death of neurons in the cerebellum. [7] Since loss of miRNA led to cerebellar degeneration, her findings highlight the potential role for dysregulation of miRNAs in neurodegenerative diseases. [7] Further highlighting the role of genetic regulation in brain homeostasis, Schaefer showed in 2009 that a deficiency in the histone methyltransferase complex GLP/G9a leads to defects in learning, motivation, and environmental adaptation in rodents. [8] Histone methyltransferases are a key regulator in gene expression. They manipulate the state of DNA, which can be either open, referred to as euchromatin or closed, referred to as heterochromatin. [8] Later in her postdoc, Schafer helped elucidate the role of transcriptional regulation in the context of drug addiction in mice. [9] She found that a deficiency in argonaute 2 (a gene known to regulate the generation of miRNA) in the dopamine receptor 2 (Drd2) positive cells in the striatum caused a decrease in the motivation to seek cocaine. [9] Schaefer further explored which miRNAs are modulated by argonaute 2 to elucidate specifically which miRNAs might be important in mediating addition to cocaine. [9]

Once Schaefer started her lab at Mount Sinai, she continued to probe the role of transcriptional regulation on neuronal function and driving behavior. In 2013, she published a paper in Science showing that a specific miRNA, miRNA-128, governs neuronal excitability and motor behavior in mice. [10] When they suppressed this miRNA, aberrant motor patterns and fatal epilepsy resulted. [10] Seeing how critical the presence of this one miRNA seemed to be in regulating neuronal excitability, Schaefer and Greengard filed a patent for using miRNA manipulation as a treatment for motor diseases and seizures. [10] Overall, Schaefer's work has highlighted the importance of understanding epigenetics and transcriptional regulation in the context of brain related diseases.

Epigenetics and autism spectrum disorders

Schaefer's work has also increased our understanding of the epigenetic mechanisms contributing to Autism Spectrum Disorders. Her lab identified the bromodomain and extraterminal domain-containing proteins (BETs) as potent regulators of genes involved in generating ASD-type behaviors in mouse models. [11] When they suppressed BET proteins they found decreased neuronal gene expression and neuronal dysfunction which suggested a role for the BET-controlled gene network in ASD. [11] Following up on this work, Schaefer and her colleagues hypothesized that ASDs are disorders of gene regulatory networks which are inevitably influenced by both genetic and environmental factors, consistent with broad array of factors that we find linked to ASD development in humans. [12]

Epigenetics and microglia

Another facet of Schaefer's work is understanding the impact of epigenetic regulation on neuroimmunity, with a particular focus on the innate immune cells of the brain, microglia. [6] In a paper published in Nature Neuroscience in 2018, Schaefer and her colleagues showed that epigenetic regulation underlies differences in microglial behavior across different brain regions. [13] They found that baseline phagocytic activity of microglia was high in the cerebellum but low in the striatum. [13] Using the TRAP technique developed by Schaefer in 2011, they discovered that the polycomb repressive complex 2 (PRC2), which mediates repressive chromatin modifications, is actively repressing phagocytic phenotypes and morphological changes in striatal microglia. [13] When they inhibited PRC2, microglia exhibited robust phagocytic activity even in the absence of dying neurons. [13] These findings highlighted a critical role for epigenetic regulation of microglia in diseases where aberrantly activated microglia lead to over-pruning and neurodegeneration. [13] To understand more deeply what drives the unique epigenetic programming of cerebellar versus striatal microglia, Schaefer collaborated with Dr. Miriam Merad’s group at Sinai to look at ontology of cerebellar versus striatal microglia. [14] They found that cerebellar microglial identity was driven by interactions between CSF-1 and the CSF-1 receptor, and was not reliant on the alternate CSF-1R ligand, IL-34. [14] When they depleted CSF-1, it led to disruptions in cerebellar microglia development as well as cerebellar neuron function but had no effect on the development of forebrain microglia. [14]

Pharmaceutical industry involvement

In addition to her academic involvements, Schaefer is also a consultant for the pharmaceutical company Neuroinflammation NewCo and is involved in the committees and data safety monitoring of Eli Lilly, Genentech Inc, GlaxoSmithKline, and Regenxbio. [1]

In 2011, Schaefer was part of a team that filed a patent for a method of translational profiling and molecular phenotyping of mRNAs from specific cell types. [15] The TRAP (Translating Ribosome Affinity Purification) methodology that is described in this patent provides a way to detect genes that are co-regulated within or across cell types, as well as discover candidate gene targets for treating specific neurological disorders and screen for modulators of those candidate genes. [15] The method involves isolating mRNAs that are in complex with a ribosome that is presumably in the process of translating the mRNA. [15]  The TRAP technique is now widely used by scientists to find vulnerable cell types or modulators associated with particular diseases. [16]

In 2013, Schaefer and her postdoctoral advisor, Dr. Paul Greengard, filed a patent for a therapeutic strategy to treat or reduce the likelihood of seizures. [17] Schaefer and Greengard found that the microRNA miR-128 is involved in modulating neuronal excitability and motor activity. [17] Their therapeutic strategy involves administering miR-128, an agent with 90% sequence homology, or an agent capable of increasing the expression or activity of miR-128 as a means to control dopamine receptor 1 (Drdr1) neuron excitability. [17] The agent would be administered intrathecally, intranasally, or directly to the hippocampus or cortex via an injection. [17]

Awards and honors

Selected publications

Related Research Articles

<span class="mw-page-title-main">Brain-derived neurotrophic factor</span> Protein found in humans

Brain-derived neurotrophic factor (BDNF), or abrineurin, is a protein that, in humans, is encoded by the BDNF gene. BDNF is a member of the neurotrophin family of growth factors, which are related to the canonical nerve growth factor (NGF), a family which also includes NT-3 and NT-4/NT-5. Neurotrophic factors are found in the brain and the periphery. BDNF was first isolated from a pig brain in 1982 by Yves-Alain Barde and Hans Thoenen.

<span class="mw-page-title-main">TRPC3</span> Protein and coding gene in humans

Short transient receptor potential channel 3 (TrpC3) also known as transient receptor protein 3 (TRP-3) is a protein that in humans is encoded by the TRPC3 gene. The TRPC3/6/7 subfamily are implicated in the regulation of vascular tone, cell growth, proliferation and pathological hypertrophy. These are diacylglycerol-sensitive cation channels known to regulate intracellular calcium via activation of the phospholipase C (PLC) pathway and/or by sensing Ca2+ store depletion. Together, their role in calcium homeostasis has made them potential therapeutic targets for a variety of central and peripheral pathologies.

<span class="mw-page-title-main">Protein BTG2</span> Protein-coding gene in the species Homo sapiens

Protein BTG2 also known as BTG family member 2 or NGF-inducible anti-proliferative protein PC3 or NGF-inducible protein TIS21, is a protein that in humans is encoded by the BTG2 gene and in other mammals by the homologous Btg2 gene. This protein controls cell cycle progression and proneural genes expression by acting as a transcription coregulator that enhances or inhibits the activity of transcription factors.

<span class="mw-page-title-main">PPP1R1B</span> Protein

Protein phosphatase 1 regulatory subunit 1B (PPP1R1B), also known as dopamine- and cAMP-regulated neuronal phosphoprotein (DARPP-32), is a protein that in humans is encoded by the PPP1R1B gene.

<span class="mw-page-title-main">RBFOX1</span> Protein-coding gene in the species Homo sapiens

Fox-1 homolog A, also known as ataxin 2-binding protein 1 (A2BP1) or hexaribonucleotide-binding protein 1 (HRNBP1) or RNA binding protein, fox-1 homolog (Rbfox1), is a protein that in humans is encoded by the RBFOX1 gene.

<span class="mw-page-title-main">Eric J. Nestler</span> Neuroscientist of addiction and depression

Eric J. Nestler is the Nash Family Professor of Neuroscience, Director of the Friedman Brain Institute, and Dean for Academic Affairs at the Icahn School of Medicine at Mount Sinai and Chief Scientific Officer of the Mount Sinai Health System. His research is focused on a molecular approach to drug addiction and depression.

Michael L. Brodman is an American gynecologist and obstetrician and currently the Ellen and Howard C. Katz Professor and Chairman of the Department of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Hospital, Mount Sinai Health System, and Icahn School of Medicine at Mount Sinai in New York City. He is recognized internationally as a pioneer in the field of urogynecology.

<span class="mw-page-title-main">Ming-Ming Zhou</span>

Ming-Ming Zhou is an American scientist whose specification is structural and chemical biology, NMR spectroscopy, and drug design. He is the Dr. Harold and Golden Lamport Professor and Chairman of the Department of Pharmacological Sciences. He is also the co-director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System in New York City, as well as Professor of Sciences. Zhou is an elected fellow of the American Association for the Advancement of Science.

<span class="mw-page-title-main">KCTD7</span> Protein-coding gene in the species Homo sapiens

Potassium channel tetramerisation domain containing 7 is a protein in humans that is encoded by the KCTD7 gene. Alternative splicing results in multiple transcript variants.

Epigenetic regulation of neurogenesis is the role that epigenetics plays in the regulation of neurogenesis.

Joseph D. Buxbaum is an American molecular and cellular neuroscientist, autism researcher, and the Director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai. Buxbaum is also, along with Simon Baron-Cohen, the co-editor of the BioMed Central journal Molecular Autism, and is a member of the scientific advisory board of the Autism Science Foundation. Buxbaum is a Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences. He is also the Vice Chair for Research and for Mentoring in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.

<span class="mw-page-title-main">Antonello Bonci</span> American physician

Antonello Bonci is an Italian-American neurologist and a neuropsychopharmacologist specialized in the long-term effects of drug exposure on the brain. In August 2019, he became president of Global Institutes on Addictions Miami. Bonci was previously the scientific director of the National Institute on Drug Abuse and a professor at the University of California, San Francisco.

<span class="mw-page-title-main">Ventricular zone</span> Transient embryonic layer of tissue containing neural stem cells

In vertebrates, the ventricular zone (VZ) is a transient embryonic layer of tissue containing neural stem cells, principally radial glial cells, of the central nervous system (CNS). The VZ is so named because it lines the ventricular system, which contains cerebrospinal fluid (CSF). The embryonic ventricular system contains growth factors and other nutrients needed for the proper function of neural stem cells. Neurogenesis, or the generation of neurons, occurs in the VZ during embryonic and fetal development as a function of the Notch pathway, and the newborn neurons must migrate substantial distances to their final destination in the developing brain or spinal cord where they will establish neural circuits. A secondary proliferative zone, the subventricular zone (SVZ), lies adjacent to the VZ. In the embryonic cerebral cortex, the SVZ contains intermediate neuronal progenitors that continue to divide into post-mitotic neurons. Through the process of neurogenesis, the parent neural stem cell pool is depleted and the VZ disappears. The balance between the rates of stem cell proliferation and neurogenesis changes during development, and species from mouse to human show large differences in the number of cell cycles, cell cycle length, and other parameters, which is thought to give rise to the large diversity in brain size and structure.

<span class="mw-page-title-main">Giulio Maria Pasinetti</span>

Giulio Maria Pasinetti is the Program Director of the Center on Molecular Integrative Neuroresilience and is the Saunders Family Chair in Neurology at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York City. Pasinetti is a Professor of Neurology, Psychiatry, Neuroscience, and Geriatrics and Palliative Medicine at ISMMS.

Alison Mary Goate is the Jean C. and James W. Crystal Professor and Chair of the Department of Genetics and Genomic Sciences and Director of the Loeb Center for Alzheimer's Disease at Icahn School of Medicine at Mount Sinai, New York City. She was previously professor of genetics in psychiatry, professor of genetics, and professor of neurology at Washington University School of Medicine.

R. Suzanne Zukin is an American neuroscientist and a professor of neuroscience who directs a research lab as a F. M. Kirby Chair in Neural Repair and Protection and director of the Neuropsychopharmacology Center at Albert Einstein College of Medicine. Zukin's areas of research include neurodegenerative disorders, Ischemia, Epigenetics and Autism and uses molecular biology approaches to research these disorders. Zukin has made seminal contributions to the understanding of NMDA and AMPA receptor function and activity.

René Sylvain Kahn is a neuropsychiatrist and the Esther and Joseph Klingenstein Professor and System Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai in the United States, a position he has held since 2017. He previously served as Professor of Psychiatry and Director of the Brain Center Rudolf Magnus at the University Medical Center Utrecht in the Netherlands. Kahn is recognized for his research on the neurobiology of schizophrenia. He served as a former president of the Schizophrenia International Research Society and was elected to the Royal Netherlands Academy of Arts and Sciences in 2009. He received the Neuropsychopharmacology Award from the European College of Neuropsychopharmacology in 2014.

Patrizia Casaccia is an Italian neuroscientist who is the Director of the Neuroscience Initiative of the Advanced Science Research Center at the CUNY Graduate Center, as well as a Professor of Neuroscience, Genetics & Genomics, and Neurology at the Icahn School of Medicine at Mount Sinai. Casaccia is a pioneer in the study of myelin. Her research focuses on understanding the neurobiological and neuroimmune mechanisms of multiple sclerosis and to translate findings into treatments. Casaccia co-founded the Center for Glial Biology at Mount Sinai and CUNY and is one of the Directors of the center.

<span class="mw-page-title-main">Brain cell</span> Functional tissue of the brain

Brain cells make up the functional tissue of the brain. The rest of the brain tissue is structural or connective called the stroma which includes blood vessels. The two main types of cells in the brain are neurons, also known as nerve cells, and glial cells, also known as neuroglia.

Zhenyu Yue is a Chinese academic researcher in the field of neurology and neuroscience, who is the Alex and Shirley Aidekman Professor at the Icahn School of Medicine at Mount Sinai, New York. He is known for his discovery of genes controlling autophagy, autophagy functions in central nervous system, molecular mechanism of neurodegenerative diseases, and modelling neurological diseases using genetic mouse models.

References

  1. 1 2 3 4 5 6 7 8 9 10 "Anne Schaefer | Icahn School of Medicine". Icahn School of Medicine at Mount Sinai. Retrieved 2020-04-13.
  2. 1 2 3 4 "Loop | Anne Schaefer". loop.frontiersin.org. Retrieved 2020-04-13.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 "My Bibliography - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2020-04-13.
  4. ↑ Wardemann, Hedda; Yurasov, Sergey; Schaefer, Anne; Young, James W.; Meffre, Eric; Nussenzweig, Michel C. (2003-09-05). "Predominant autoantibody production by early human B cell precursors". Science. 301 (5638): 1374–1377. Bibcode:2003Sci...301.1374W. doi: 10.1126/science.1086907 . ISSN   1095-9203. PMID   12920303. S2CID   43459065.
  5. ↑ "NIH Director's New Innovator Award Program - 2012 Award Recipients | NIH Common Fund". commonfund.nih.gov. Retrieved 2020-04-13.
  6. 1 2 3 4 5 6 7 8 9 10 11 "Schaefer Lab | Neuroscience Labs - Icahn School of Medicine". labs.neuroscience.mssm.edu. Retrieved 2020-04-13.
  7. 1 2 3 Schaefer, Anne; O'Carroll, Dónal; Tan, Chan Lek; Hillman, Dean; Sugimori, Mutsuyuki; Llinas, Rodolfo; Greengard, Paul (2007-07-09). "Cerebellar neurodegeneration in the absence of microRNAs". The Journal of Experimental Medicine. 204 (7): 1553–1558. doi:10.1084/jem.20070823. ISSN   0022-1007. PMC   2118654 . PMID   17606634.
  8. 1 2 Schaefer, Anne; Sampath, Srihari C.; Intrator, Adam; Min, Alice; Gertler, Tracy S.; Surmeier, D. James; Tarakhovsky, Alexander; Greengard, Paul (2009-12-10). "Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex". Neuron. 64 (5): 678–691. doi:10.1016/j.neuron.2009.11.019. ISSN   1097-4199. PMC   2814156 . PMID   20005824.
  9. 1 2 3 Schaefer, Anne; Im, Heh-In; Venø, Morten T.; Fowler, Christie D.; Min, Alice; Intrator, Adam; Kjems, Jørgen; Kenny, Paul J.; O'Carroll, Donal; Greengard, Paul (2010-08-30). "Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction". The Journal of Experimental Medicine. 207 (9): 1843–1851. doi:10.1084/jem.20100451. ISSN   1540-9538. PMC   2931161 . PMID   20643829.
  10. 1 2 3 Tan, Chan Lek; Plotkin, Joshua L.; Venø, Morten T.; von Schimmelmann, Melanie; Feinberg, Philip; Mann, Silas; Handler, Annie; Kjems, Jørgen; Surmeier, D. James; O'Carroll, Dónal; Greengard, Paul (2013-12-06). "MicroRNA-128 governs neuronal excitability and motor behavior in mice". Science. 342 (6163): 1254–1258. Bibcode:2013Sci...342.1254T. doi:10.1126/science.1244193. ISSN   1095-9203. PMC   3932786 . PMID   24311694.
  11. 1 2 Sullivan, Josefa M.; Badimon, Ana; Schaefer, Uwe; Ayata, Pinar; Gray, James; Chung, Chun-wa; von Schimmelmann, Melanie; Zhang, Fan; Garton, Neil; Smithers, Nicholas; Lewis, Huw (2015-10-19). "Autism-like syndrome is induced by pharmacological suppression of BET proteins in young mice". The Journal of Experimental Medicine. 212 (11): 1771–1781. doi:10.1084/jem.20151271. ISSN   1540-9538. PMC   4612093 . PMID   26392221.
  12. ↑ Sullivan, Josefa M.; De Rubeis, Silvia; Schaefer, Anne (December 2019). "Convergence of spectrums: neuronal gene network states in autism spectrum disorder". Current Opinion in Neurobiology. 59: 102–111. doi:10.1016/j.conb.2019.04.011. ISSN   1873-6882. PMC   6888864 . PMID   31220745.
  13. 1 2 3 4 5 Ayata, Pinar; Badimon, Ana; Strasburger, Hayley J.; Duff, Mary Kaye; Montgomery, Sarah E.; Loh, Yong-Hwee E.; Ebert, Anja; Pimenova, Anna A.; Ramirez, Brianna R.; Chan, Andrew T.; Sullivan, Josefa M. (August 2018). "Epigenetic regulation of brain region-specific microglia clearance activity". Nature Neuroscience. 21 (8): 1049–1060. doi:10.1038/s41593-018-0192-3. ISSN   1097-6256. PMC   6090564 . PMID   30038282.
  14. 1 2 3 Kana, Veronika; Desland, Fiona A.; Casanova-Acebes, Maria; Ayata, Pinar; Badimon, Ana; Nabel, Elisa; Yamamuro, Kazuhiko; Sneeboer, Marjolein; Tan, I.-Li; Flanigan, Meghan E.; Rose, Samuel A. (2019-10-07). "CSF-1 controls cerebellar microglia and is required for motor function and social interaction". The Journal of Experimental Medicine. 216 (10): 2265–2281. doi:10.1084/jem.20182037. ISSN   1540-9538. PMC   6781012 . PMID   31350310.
  15. 1 2 3 EP 2265730,Heintz, Nathaniel; Greengard, Paul& Heiman, Myriamet al.,"Methods and compositions for translational profiling and molecular phenotyping",published 2010-12-29, assigned to The Rockefeller University
  16. ↑ "The TRAP technique gets back to basics | Bio 2.0 | Learn Science at Scitable". www.nature.com. Retrieved 2020-04-13.
  17. 1 2 3 4 WO 2015066034,Schaefer, Anne&Greengard, Paul,"Compositions and methods for modulating neuronal excitability and motor behavior",published 2015-05-07, assigned to Icahn School of Medicine at Mount Sinai and The Rockefeller University
  18. ↑ "Hearing from NARSAD Young Investigators (Part 3)". Brain & Behavior Research Foundation. 2011-02-14. Retrieved 2020-04-13.
  19. 1 2 "Mount Sinai Researcher Receives Prestigious National Institutes of Health Award | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2020-04-13.
  20. ↑ "Anne Schaefer, MD, PhD, of Mount Sinai School of Medicine Receives Prestigious National Institutes of Health Director's New Innovator Award | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2020-04-13.
  21. 1 2 3 4 "The Center for Glial Biology | Icahn School of Medicine". Icahn School of Medicine at Mount Sinai. Retrieved 2020-04-13.
  22. ↑ "Anne Schaefer, M.D., Ph.D. Landis Award for Outstanding Mentorship 2018". National Institutes of Neurological Disorders and Stroke. April 2018. Archived from the original on 2019-10-09. Retrieved April 12, 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.